Publication | Open Access

Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)

Rheumatoid DisorderRheumatologyEpidemiologyAutoimmune DiseaseOther Autoimmune DiseasesAdverse EventRheumatic DiseasesPatient SafetyBiologics ApprovedInflammatory Rheumatic DiseaseMedicineRheumatoid ArthritisAdverse Drug Reaction